Multiple myeloma science from EHA 2019

CAR T-cell therapy for treating acute leukaemia

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Chemoimmunotherapy or BTK inhibition for patients with CLL

The changing landscape of AML

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML

Targeted treatment of AML using T cell recruiting antibody constructs

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer

Are PARP inhibitors a new standard of care option for MBC patients?